Search

Your search keyword '"Yeh, Ming-Lun"' showing total 1,009 results
Start Over Author "Yeh, Ming-Lun"
1,009 results on '"Yeh, Ming-Lun"'

51. Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

Author

Jang, Tyng‐Yuan, primary, Liang, Po‐Cheng, additional, Jun, Dae Won, additional, Jung, Jang Han, additional, Toyoda, Hidenori, additional, Wang, Chih‐Wen, additional, Yuen, Man‐Fung, additional, Cheung, Ka Shing, additional, Yasuda, Satoshi, additional, Kim, Sung Eun, additional, Yoon, Eileen L., additional, An, Jihyun, additional, Enomoto, Masaru, additional, Kozuka, Ritsuzo, additional, Chuma, Makoto, additional, Nozaki, Akito, additional, Ishikawa, Toru, additional, Watanabe, Tsunamasa, additional, Atsukawa, Masanori, additional, Arai, Taeang, additional, Hayama, Korenobu, additional, Ishigami, Masatoshi, additional, Cho, Yong Kyun, additional, Ogawa, Eiichi, additional, Kim, Hyoung Su, additional, Shim, Jae‐Jun, additional, Uojima, Haruki, additional, Jeong, Soung Won, additional, Ahn, Sang Bong, additional, Takaguchi, Koichi, additional, Senoh, Tomonori, additional, Buti, Maria, additional, Vargas‐Accarino, Elena, additional, Abe, Hiroshi, additional, Takahashi, Hirokazu, additional, Inoue, Kaori, additional, Huang, Jee‐Fu, additional, Chuang, Wan‐Long, additional, Yeh, Ming‐Lun, additional, Dai, Chia‐Yen, additional, Huang, Chung‐Feng, additional, Nguyen, Mindie H., additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

53. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Author

Lu, Ming-Ying, Chen, Chun-Ting, Shih, Yu-Lueng, Tsai, Pei-Chien, Hsieh, Meng-Hsuan, Huang, Chung-Feng, Yeh, Ming-Lun, Huang, Ching-I, Wang, Shu-Chi, Tsai, Yi-Shan, Ko, Yu-Min, Lin, Ching-Chih, Chen, Kuan-Yu, Wei, Yu-Ju, Hsu, Po-Yao, Hsu, Cheng-Ting, Jang, Tyng-Yuan, Liu, Ta-Wei, Liang, Po-Cheng, Hsieh, Ming-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Chang, Wen-Yu

Published
2021
Full Text
View/download PDF

54. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

55. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues

Author

Jang, Tyng-Yuan, Wei, Yu-Ju, Liu, Ta-Wei, Yeh, Ming-Lun, Liu, Shu-Fen, Hsu, Cheng-Ting, Hsu, Po-Yao, Lin, Yi-Hung, Liang, Po-Cheng, Hsieh, Meng-Hsuan, Ko, Yu-Min, Tsai, Yi-Shan, Chen, Kuan-Yu, Lin, Ching-Chih, Tsai, Pei-Chien, Wang, Shu-Chi, Huang, Ching-I., Lin, Zu-Yau, Chen, Shinn-Cherng, Chuang, Wan-Long, Huang, Jee-Fu, Dai, Chia-Yen, Huang, Chung-Feng, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

56. Third vaccine boosters and anti‐S‐IgGlevels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma

Author

Wang, Chih‐Wen, Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I., Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, and Yu, Ming‐Lung

Abstract

The immune response of patients with chronic liver disease tends to be lower after receiving their second coronavirus disease 2019 (COVID‐19) vaccine dose, but the effect of a third vaccine dose on their immune response is currently unknown. We recruited 722 patients without previous severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection from three hospitals. The patients received homologous (MMM) and heterologous (AZAZBNT, AZAZM) boosters, where AZ, BNT, and M denoted the AZD1222, BNT162b2, and mRNA‐1273 vaccines, respectively. Serum IgG spike antibody levels were measured at a mean 1.5 ± 0.7 (visit 1) and 5.0 ± 0.5 (visit 2) months after the third vaccine booster. A threshold of 4160 AU/mL was considered significant antibody activity. In both visits, the patients who received the MMM booster had higher anti‐S‐IgG levels than those who received the AZAZBNT and AZAZM boosters. Patients with active hepatocellular carcinoma (HCC) had lower anti‐S‐IgG levels than the control group (761.6 vs. 1498.2 BAU/mL; p= 0.019) at visit 1. The anti‐S‐IgG levels decreased significantly at visit 2. The patients with significant antibody activity had a lower rate of liver cirrhosis with decompensation (0.7% decompensation vs. 8.0% non‐decompensation and 91.3% non‐liver cirrhosis, p= 0.015), and active HCC (1.5% active HCC vs. 3.7% non‐active HCC and 94.7% non‐HCC, p< 0.001). Receiving the MMM booster regimen (OR = 10.67, 95% CI 5.20–21.91, p< 0.001) increased the odds of having significant antibody activity compared with the AZAZBNT booster regimen. Patients with active HCC had a reduced immune response to the third COVID‐19 vaccine booster. These findings underscore the importance of booster vaccinations, especially in immunocompromised patients, with superior efficacy observed with the homologous mRNA‐1273 regimen.

Published
2024
Full Text
View/download PDF

57. Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLDpatients with or without viral hepatitis

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Hsu, Po‐Yao, Tsai, Pei‐Chien, Wei, Yu‐Ju, Yeh, Ming‐Lun, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Huang, Chao‐Kuan, Dai, Chia‐Yen, Huang, Jee‐Fu, Chuang, Wan‐Long, and Yu, Ming‐Lung

Abstract

The accuracy of noninvasive seromarkers in predicting liver fibrosis in metabolic dysfunction‐associated fatty liver disease (MAFLD) patients with or without viral hepatitis is elusive. The AST to platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a viral hepatitis‐endemic area. The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the three biomarkers. APRI (AUROC range 0.73–0.80) and FIB‐4 (AUROC range 0.66–0.82) performed better than NFS (AUROC range 0.63–0.75). When patients were divided into viral and non‐viral MAFLD groups, a better AUROC of APRI (range 0.76–0.80) and FIB‐4 (range 0.68–0.78) than NFS (range 0.62–70) existed only in viral MALFD but not in non‐viral MAFLD. Regarding the NFS, the AUROC was higher in non‐viral MAFLD (range 0.69–0.86) and outperformed viral MAFLD at all fibrotic stages. The accuracy in predicting liver fibrosis increased with the advancement of liver disease for the three biomarkers. NFS exerted better diagnostic accuracy in non‐viral than in viral MAFLD patients across different fibrotic stages. The best accuracy was 91.1% using the cutoff value of −9.98 for the NFS in predicting liver cirrhosis in non‐viral MAFLD patients. The APRI and FIB‐4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients. Caution should be taken when assessing the NFS in MAFLD patients with viral hepatitis.

Published
2024
Full Text
View/download PDF

59. Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease.

Author

Jang, Tyng‐Yuan, Ho, Chi‐Chang, Liang, Po‐Cheng, Wu, Chih‐Da, Wei, Yu‐Ju, Tsai, Pei‐Chien, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Hsieh, Meng‐Hsuan, Wang, Chih‐Wen, Yang, Jeng‐Fu, Yeh, Ming‐Lun, Huang, Chung‐Feng, Chuang, Wan‐Long, Huang, Jee‐Fu, Cheng, Ya‐Yun, Dai, Chia‐Yen, Chen, Pau‐Chung, and Yu, Ming‐Lung

Subjects
AIR pollution, HEPATIC fibrosis, CHRONICALLY ill, AIR pollutants, CHRONIC hepatitis B
Abstract

We aimed to investigate the association between air pollution and advanced fibrosis among patients with metabolic associated fatty liver disease (MAFLD) and chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A total of 1376 participants who were seropositive for HBV surface antigen (HBsAg) or antibodies to HCV (anti‐HCV) or had abnormal liver function in a community screening program from 2019 to 2021 were enrolled for the assessment of liver fibrosis using transient elastography. Daily estimates of air pollutants (particulate matter ≤2.5 μm in diameter [PM2.5], nitrogen dioxide [NO2], ozone [O3] and benzene) were aggregated into mean estimates for the previous year based on the date of enrolment. Of the 1376 participants, 767 (52.8%) and 187 (13.6) had MAFLD and advanced fibrosis, respectively. A logistic regression analysis revealed that the factors associated with advanced liver fibrosis were HCV viremia (odds ratio [OR], 3.13; 95% confidence interval [CI], 2.05–4.77; p < 0.001), smoking (OR, 1.79; 95% CI, 1.16–2.74; p = 0.01), age (OR, 1.04; 95% CI, 1.02–1.05; p < 0.001) and PM2.5 (OR, 1.10; 95% CI, 1.05–1.16; p < 0.001). Linear regression analysis revealed that LSM was independently correlated with PM2.5 (β: 0.134; 95% CI: 0.025, 0.243; p = 0.02). There was a dose‐dependent relationship between different fibrotic stages and the PM2.5 level (the PM2.5 level in patients with fibrotic stages 0, 1–2 and 3–4: 27.9, 28.4, and 29.3 μg/m3, respectively; trend p < 0.001). Exposure to PM2.5, as well as HBV and HCV infections, is associated with advanced liver fibrosis in patients with MAFLD. There was a dose‐dependent correlation between PM2.5 levels and the severity of hepatic fibrosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

60. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.

Author

Ogawa, Eiichi, Jun, Dae Won, Toyoda, Hidenori, Hsu, Yao‐Chun, Yoon, Eileen L., Ahn, Sang Bong, Yeh, Ming‐Lun, Do, Son, Trinh, Huy N., Takahashi, Hirokazu, Enomoto, Masaru, Kawada, Norifumi, Yasuda, Satoshi, Tseng, Cheng‐Hao, Kawashima, Keigo, Lee, Han Ah, Inoue, Kaori, Haga, Hiroaki, Do, Ai‐Thien, and Maeda, Mayumi

Subjects
CHRONIC hepatitis B, BONE density, SPINE, TENOFOVIR, ALANINE aminotransferase, GLOMERULAR filtration rate
Abstract

Summary: Background: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited. Aims: To assess the treatment and renal/bone safety outcomes following the switch to TAF. Methods: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T‐scores (L‐spine) by bone absorptiometry by 24 months after switch to TAF. Results: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T‐score improved significantly from −1.43 ± 1.36 to −1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9–89.5 ± 16.3 mL/min/1.73 m2, p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T‐score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T‐score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019). Conclusions: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

61. Patient‐centered and integrated outreach care for chronic hepatitis C patients with serious mental illness in Taiwan.

Author

Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yu, Shun‐Chieh, Huang, Shin‐Chung, Ho, Shao‐Lun, Yeh, Ming‐Lun, Wang, Chih‐Wen, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Yu, Sung‐Lin, Wu, Pey‐Fang, Chen, Yu‐Han, Chien, Shin‐Chi, Huang, Jee‐Fu, Dai, Chia‐Yen, and Chuang, Wan‐Long

Subjects
PEOPLE with mental illness, CHRONIC hepatitis C, HEPATITIS C, HEPATITIS C virus, DELAYED diagnosis, DISEASE risk factors, PSYCHIATRIC nursing
Abstract

Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary outreach screening followed by HCV reflex testing and onsite treatment for schizophrenia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microelimination effectiveness, defined as the multiplication of the rates of anti‐HCV antibodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post‐treatment follow‐up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy‐three (4.9%) individuals were seropositive for anti‐HCV antibodies. Of the 73 anti‐HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty‐three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post‐treatment follow‐up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient‐centered and integrated outreach program facilitated HCV care in this marginalized population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

62. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area.

Author

Huang, Chung‐Feng, Liang, Po‐Cheng, Tsai, Pei‐Chien, Wei, Yu‐Ju, Huang, Ching‐I, Wang, Chih‐Wen, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Hsu, Po‐Yao, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Dai, Chia‐Yen, Chuang, Wan‐Long, Huang, Jee‐Fu, and Yu, Ming‐Lung

Subjects
FATTY liver, VIRAL hepatitis, LIVER diseases, VIRUS diseases, HEPATITIS C virus
Abstract

Background and Aim: The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive. Methods: A mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non‐MAFLD subjects with advanced liver disease. Results: Two thousand two hundred and forty‐two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti‐HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non‐viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, P < 0.001), male sex (OR/CI: 1.3/1.0–1.7, P = 0.019), anti‐HCV seropositivity (OR/CI: 5.9/4.6–7.5, P = 0.019), MAFLD‐lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3–5.2, P = 0.005; compared with the non‐MAFLD group) and MAFLD‐diabetes (OR/CI: 1.5/1.1–2.1, P = 0.008; compared with the non‐MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD‐lean MS group (OR/CI: 9.1/2.4–34.6, P = 0.001; compared with non‐MAFLD group) and MAFLD‐DM group (OR/CI: 2.0/1.2–3.2, P = 0.004; compared with non‐MAFLD group). Conclusions: MAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non‐viral hepatitis subjects in a community level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

63. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

Author

Huang, Chung‐Feng, primary, Liang, Po‐Cheng, additional, Tsai, Pei‐Chien, additional, Wei, Yu‐Ju, additional, Huang, Ching‐I, additional, Wang, Chih‐Wen, additional, Jang, Tyng‐Yuan, additional, Yeh, Ming‐Lun, additional, Hsu, Po‐Yao, additional, Hsieh, Ming‐Yen, additional, Lin, Yi‐Hung, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, Huang, Jee‐Fu, additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

65. Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinoma

Author

Lee, Kuan‐I, primary, Liang, Po‐Cheng, additional, Hsu, Po‐Yau, additional, Jang, Tyng‐Yuan, additional, Wei, Yu‐Ju, additional, Huang, Ching‐I, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2023
Full Text
View/download PDF

66. Sex differences in treatment response to nucleos(t)ide therapy in chronic hepatitis B: a multicenter longitudinal study

Author

Chau, Angela, primary, Yeh, Ming-Lun, additional, Tsai, Pei-Chien, additional, Huang, Daniel Q., additional, Kim, Sung Eun, additional, Trinh, Huy, additional, Yoon, Eileen L., additional, Oh, Hyunwoo, additional, Jeong, Jae Yoon, additional, Ahn, Sang Bong, additional, An, Jihyun, additional, Tseng, Cheng-Hao, additional, Hsu, Yao-Chun, additional, Jeong, Soung Won, additional, Cho, Yong Kyun, additional, Shim, Jae-Jun, additional, Kim, Hyoung Su, additional, Ito, Takanori, additional, Marciano, Sebastián, additional, Kawashima, Keigo, additional, Suzuki, Takanori, additional, Watanabe, Tsunamasa, additional, Nozaki, Akito, additional, Ishikawa, Toru, additional, Inoue, Kaori, additional, Eguchi, Yuichiro, additional, Uojima, Haruki, additional, Abe, Hiroshi, additional, Takahashi, Hirokazu, additional, Chuma, Makoto, additional, Ishigami, Masatoshi, additional, Hoang, Joseph K., additional, Mayumi, Maeda, additional, Huang, Chung-Feng, additional, Gadano, Adrian, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Tanaka, Yasuhito, additional, Chuang, Wan-Long, additional, Lim, Seng Gee, additional, Cheung, Ramsey, additional, Yu, Ming-Lung, additional, Jun, Dae-Won, additional, and Nguyen, Mindie H., additional

Published
2023
Full Text
View/download PDF

70. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort

Author

Huang, Chung-Feng, primary, Jang, Tyng-Yuan, additional, Wu, Ping-Hsun, additional, Kuo, Mei-Chuan, additional, Yeh, Ming-Lun, additional, Wang, Chih-Wen, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Huang, Ching-I, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Hsiao, Hui-Hua, additional, Hsu, Chin-Mu, additional, Huang, Chien-Tzu, additional, Lee, Chun-Yuan, additional, Chen, Yen-Hsu, additional, Chen, Tun-Chieh, additional, Lin, Kun-Der, additional, Wang, Shuo-Hung, additional, Wang, Sheng-Fan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

71. The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry

Author

Huang, Chung-Feng, primary, Kuo, Hsing-Tao, additional, Chang, Te-Sheng, additional, Lo, Ching-Chu, additional, Hung, Chao-Hung, additional, Huang, Chien-Wei, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Bair, Ming-Jong, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Wang, Sih-Ren, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Shengshun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Mou, Lien-Juei, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Jia-Sheng, additional, Chen, Guei-Ying, additional, Gao, Jian-Neng, additional, Tai, Chi-Ming, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Chen, Chiyi, additional, Tseng, Kuo-Chih, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

72. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan

Author

Yu, Ming-Lung, primary, Tai, Chi-Ming, additional, Mou, Lien-Juei, additional, Kuo, Hsing-Tao, additional, Huang, Chung-Feng, additional, Tseng, Kuo-Chih, additional, Lo, Chingchu, additional, Bair, Ming-Jong, additional, Wang, Sih-Ren, additional, Huang, Jee-Fu, additional, Yeh, Ming-Lun, additional, Chen, Chun-Ting, additional, Tsai, Ming-Chang, additional, Huang, Chien-Wei, additional, Lee, Pei-Lun, additional, Yang, Tzeng-Hue, additional, Huang, Yi-Hsiang, additional, Chong, Lee-Won, additional, Chen, Chien-Lin, additional, Yang, Chi-Chieh, additional, Hung, Chao-Hung, additional, Yang, Sheng-Shun, additional, Cheng, Pin-Nan, additional, Hsieh, Tsai-Yuan, additional, Hu, Jui-Ting, additional, Wu, Wen-Chih, additional, Cheng, Chien-Yu, additional, Chen, Guei-Ying, additional, Chou, Kwok-Hsiung, additional, Tsai, Wei-lun, additional, Gao, Jian-Neng, additional, Lin, Chih-Lang, additional, Wang, Chia-Chi, additional, Lin, Ta-Ya, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Lee, Tzong-Hsi, additional, Chang, Te-Sheng, additional, Liu, Chun-Jen, additional, Dai, Chia-Yen, additional, Chen, Chi-Yi, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, and Peng, Cheng-Yuan, additional

Published
2023
Full Text
View/download PDF

73. Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease

Author

Huang, Jee-Fu, primary, Tsai, Pei-Chien, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Huang, Ching-I, additional, Lee, Mei-Hsuan, additional, Hsu, Po-Yau, additional, Wang, Chih-Wen, additional, Wei, Yu-Ju, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Hsieh, Ming-Yen, additional, Jang, Tyng-Yuan, additional, Bair, Ming-Jong, additional, Lin, Zu-Yau, additional, Dai, Chia-Yen, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2023
Full Text
View/download PDF

74. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase

Author

Huang, Daniel Q., primary, Tran, Andrew, additional, Yeh, Ming-Lun, additional, Yasuda, Satoshi, additional, Tsai, Pei-Chien, additional, Huang, Chung-Feng, additional, Dai, Chia Yen, additional, Ogawa, Eiichi, additional, Ishigami, Masatoshi, additional, Ito, Takanori, additional, Kozuka, Ritsuzo, additional, Enomoto, Masaru, additional, Suzuki, Takanori, additional, Yoshimaru, Yoko, additional, Preda, Carmen M., additional, Marin, Raluca I., additional, Sandra, Irina, additional, Tran, Sally, additional, Quek, Sabrina X.Z., additional, Khine, Htet Htet Toe Wai, additional, Itokawa, Norio, additional, Atsukawa, Masanori, additional, Uojima, Haruki, additional, Watanabe, Tsunamasa, additional, Takahashi, Hirokazu, additional, Inoue, Kaori, additional, Maeda, Mayumi, additional, Hoang, Joseph K., additional, Trinh, Lindsey, additional, Barnett, Scott, additional, Cheung, Ramsey, additional, Lim, Seng Gee, additional, Trinh, Huy N., additional, Chuang, Wan-Long, additional, Tanaka, Yasuhito, additional, Toyoda, Hidenori, additional, Yu, Ming-Lung, additional, and Nguyen, Mindie H., additional

Published
2023
Full Text
View/download PDF

75. Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

Author

Jang, Tyng‐Yuan, Liang, Po‐Cheng, Jun, Dae Won, Jung, Jang Han, Toyoda, Hidenori, Wang, Chih‐Wen, Yuen, Man‐Fung, Cheung, Ka Shing, Yasuda, Satoshi, Kim, Sung Eun, Yoon, Eileen L., An, Jihyun, Enomoto, Masaru, Kozuka, Ritsuzo, Chuma, Makoto, Nozaki, Akito, Ishikawa, Toru, Watanabe, Tsunamasa, Atsukawa, Masanori, Arai, Taeang, Hayama, Korenobu, Ishigami, Masatoshi, Cho, Yong Kyun, Ogawa, Eiichi, Kim, Hyoung Su, Shim, Jae‐Jun, Uojima, Haruki, Jeong, Soung Won, Ahn, Sang Bong, Takaguchi, Koichi, Senoh, Tomonori, Buti, Maria, Vargas‐Accarino, Elena, Abe, Hiroshi, Takahashi, Hirokazu, Inoue, Kaori, Huang, Jee‐Fu, Chuang, Wan‐Long, Yeh, Ming‐Lun, Dai, Chia‐Yen, Huang, Chung‐Feng, Nguyen, Mindie H., and Yu, Ming‐Lung

Abstract

Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month‐6) after initiating NAs were measured to explore their association with all‐cause, liver‐related, and non‐liver‐related mortality. The annual incidence of all‐cause mortality was 0.9/100 person‐years over a follow‐up period of 17,436.3 person‐years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p= 0.002) and Month‐6‐GGT levels (62.1 vs. 38.4 U/L, p< 0.001). The factors associated with all‐cause mortality included cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92–3.70, p< 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003–1.006, p< 0.001), alanine aminotransferase level (HR/CI: 0.996/0.994–0.998, p= 0.001), and age (HR/CI: 1.06/1.04–1.07, p< 0.001). Regarding liver‐related mortality, the independent factors included cirrhosis (HR/CI: 4.36/2.79–6.89, p< 0.001), pretreatment GGT levels (HR/CI: 1.006/1.004–1.008, p< 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990–0.997, p= 0.001), age (HR/CI: 1.03/1.01–1.05, p< 0.001), and fatty liver disease (HR/CI: 0.30/0.15–0.59, p= 0.001). Pretreatment GGT levels were also independently predictive of non‐liver‐related mortality (HR/CI: 1.003/1.000–1.005, p= 0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose‐dependent manner of <25, 25–75, and >75 percentile of pretreatment GGT levels was observed with respect to the all‐cause mortality (trend p< 0.001). Pretreatment serum GGT levels predicted all‐cause, liver‐related, and non‐liver‐related mortality in patients with CHB treated with NAs.

Published
2024
Full Text
View/download PDF

76. Patient‐centered and integrated outreach care for chronic hepatitis Cpatients with serious mental illness in Taiwan

Author

Huang, Chung‐Feng, Jang, Tyng‐Yuan, Yu, Shun‐Chieh, Huang, Shin‐Chung, Ho, Shao‐Lun, Yeh, Ming‐Lun, Wang, Chih‐Wen, Liang, Po‐Cheng, Wei, Yu‐Ju, Hsu, Po‐Yao, Huang, Ching‐I, Hsieh, Ming‐Yen, Lin, Yi‐Hung, Yu, Sung‐Lin, Wu, Pey‐Fang, Chen, Yu‐Han, Chien, Shin‐Chi, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, Wang, Tso‐Jen, and Yu, Ming‐Lung

Abstract

Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infection but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary outreach screening followed by HCV reflex testing and onsite treatment for schizophrenia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microelimination effectiveness, defined as the multiplication of the rates of anti‐HCV antibodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post‐treatment follow‐up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy‐three (4.9%) individuals were seropositive for anti‐HCV antibodies. Of the 73 anti‐HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty‐three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post‐treatment follow‐up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient‐centered and integrated outreach program facilitated HCV care in this marginalized population.

Published
2024
Full Text
View/download PDF

77. Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.

Author

Huang, Chung-Feng, Dai, Chia-Yen, Wang, Chih-Wen, Liang, Po-Cheng, Wei, Yu-Ju, Tsai, Pei-Chien, Jang, Tyng-Yuan, Hsu, Po-Yao, Lee, Jia-Jung, Niu, Sheng-Wen, Huang, Jiun-Chi, Yeh, Ming-Lun, Huang, Ching-I, Hsieh, Ming-Yen, Lin, Yi-Hung, Chen, Szu-Chia, Chiu, Yi-Wen, Huang, Jee-Fu, Chang, Jer-Ming, and Hwang, Shang-Jyh

Subjects
HEPATITIS C virus, PATIENT experience, COHORT analysis, HEMODIALYSIS, LONGITUDINAL method
Abstract

Background The World Health Organization has established interim guidance for hepatitis C virus (HCV) elimination. We aimed to prove the concept of "treatment as prevention" by conducting a prospective HCV elimination program for hemodialysis (HD) patients. Methods A universal HCV screen was launched in 22 HD centers in 2019. HCV-viremic patients were linked to care with direct-acting antivirals (DAAs). The second screen was performed in 2021 to evaluate the effect of link-to-care in lowering the prevalence of HCV viremia and the incidence of HCV new/re-infections. Results Of 2336 patients enrolled in the first screening in 2019, 320 (13.7%) were seropositive for anti-HCV and 181 (7.7%) were HCV-viremic. Of 152 patients successfully linked to treat with DAA, 140 (92.1%) patients achieved a sustained virological response. Of them, 1733 patients participated in the second surveillance. Five anti-HCV-negative patients experienced anti-HCV seroconversion. Of 119 DAA-cured patients and 102 spontaneous HCV clearance patients, none had HCV reinfection. The annual incidence of HCV new infection was 0.1%. Sixty-one of the 620 (9.8%) newly enrolled patients were anti-HCV-seropositive in the second survey. The overall HCV-viremic rate decreased from 7.7% in 2019 to 0.6% (15/2353) in 2021. At the institutional level, 45.5% (10/22) eradicated HCV and 82% (18/22) of HD units had no HCV new infections or reinfections. Conclusions The link-to-care project proved the concept of "treatment as prevention" by which HCV microelimination helps to prevent reinfection and new infections in the HD population. Trial registration: ClinicalTrials.gov identifier: NCT03803410 and NCT03891550. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

78. Impact of comorbidities on the serological response to COVID-19 vaccination in Taiwan

Author

Huang, Chung-Feng, primary, Jang, Tyng-Yuan, additional, Wu, Ping-Hsun, additional, Kuo, Mei-Chuan, additional, Yeh, Ming-Lun, additional, Wang, Chih-Wen, additional, Liang, Po-Cheng, additional, Wei, Yu-Ju, additional, Hsu, Po-Yao, additional, Huang, Ching-I, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Hung, additional, Hsiao, Hui-Hua, additional, Hsu, Chin-Mu, additional, Huang, Chien-Tzu, additional, Lee, Chun-Yuan, additional, Chen, Yen-Hsu, additional, Chen, Tun-Chieh, additional, Lin, Kun-Der, additional, Wang, Shuo-Hung, additional, Wang, Sheng-Fan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2023
Full Text
View/download PDF

83. Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment

Author

Wu, Jyun-Yi, primary, Tsai, Yi-Shan, additional, Li, Chia-Chen, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Huang, Chung-Feng, additional, Hsu, Jia-Ning, additional, Hsieh, Meng-Hsuan, additional, Chen, Yo-Chia, additional, Liu, Ta-Wei, additional, Lin, Yi-Hung, additional, Liang, Po-Cheng, additional, Lin, Zu-Yau, additional, Chuang, Wan-Long, additional, Yu, Ming-Lung, additional, and Dai, Chia-Yen, additional

Published
2022
Full Text
View/download PDF

84. Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR

Author

Hsu, Po-Yao, primary, Liang, Po-Cheng, additional, Huang, Ching-I, additional, Hsieh, Meng-Hsuan, additional, Tsai, Yi-Shan, additional, Lin, Tzu-Chun, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Wang, Chih-Wen, additional, Jang, Tyng-Yuan, additional, Lin, Yi-Hung, additional, Lin, Zu-Yau, additional, Chuang, Wan-Long, additional, and Dai, Chia-Yen, additional

Published
2022
Full Text
View/download PDF

85. THU-174 - The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry

Author

Huang, Chung-Feng, Kuo, Hsing-Tao, Chang, Te-Sheng, Lo, Ching-Chu, Hung, Chao-Hung, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Sih-Ren, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Shengshun, Wang, Chia-Chi, Hu, Jui-Ting, Mou, Lien-Juei, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Jia-Sheng, Chen, Guei-Ying, Gao, Jian-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wan-Long, Chen, Chiyi, Tseng, Kuo-Chih, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

86. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma

Author

Po-Yao Hsu, Liang, Po-Cheng, Chang, Wen-Tsan, Lu, Ming-Ying, Wang, Wen-Hsuan, Chuang, Shih-Chang, Wei, Yu-Ju, Jang, Tyng-Yuan, Yeh, Ming-Lun, Huang, Ching-I, Lin, Yi-Hung, Wang, Chih-Wen, Hsieh, Ming-Yen, Hou, Nai-Jen, Hsieh, Meng-Hsuan, Tsai, Yi-Shan, Ko, Yu-Min, Lin, Ching-Chih, Chen, Kuan-Yu, Dai, Chia-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Chuang, Wan-Long, Huang, Chung-Feng, Huang, Jee-Fu, and Yu, Ming-Lung

Subjects
Original Article
Abstract

Lenvatinib has been effective not only as a first-line but also as a later-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in real-world clinical practice. How to predict the efficacy of lenvatinib and guide appropriate therapy selection in patients with uHCC have become important issues. This study aimed to investigate the impact of serum biomarkers on the treatment outcomes of patients with uHCC treated with lenvatinib in a real-world setting using an artificial intelligence algorithm. We measured serum biomarkers, including alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and circulating angiogenic factors (CAFs [i.e., vascular endothelial growth factor, angiopoietin-2, fibroblast growth factor-19 [FGF19], and FGF21]) and analyzed treatment outcomes, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) in patients with uHCC treated with lenvatinib. The results of this study demonstrated that an AFP reduction ≥ 40% from baseline within 8 weeks after lenvatinib induction was associated with a higher ORR. With baseline biomarkers using a decision tree-based model, we identified patients with high, intermediate, and low ORRs (84.6%, 21.7% and 0%, respectively; odds ratio, 53.04, P < 0.001, high versus intermediate/low groups). Based on the decision tree-based survival predictive model, baseline AFP was the most important factor for OS, followed by ALBI grade and FGF21.

Published
2022

89. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV registry

Author

Hung, Chao-Hung, primary, Chang, Te-Sheng, additional, Huang, Chung-Feng, additional, Kuo, Hsing-Tao, additional, Lo, Ching-Chu, additional, Huang, Chien-Wei, additional, Chong, Lee-Won, additional, Cheng, Pin-Nan, additional, Yeh, Ming-Lun, additional, Peng, Cheng-Yuan, additional, Cheng, Chien-Yu, additional, Huang, Jee-Fu, additional, Bair, Ming-Jong, additional, Lin, Chih-Lang, additional, Yang, Chi-Chieh, additional, Wang, Sih-Ren, additional, Hsieh, Tsai-Yuan, additional, Lee, Tzong-Hsi, additional, Lee, Pei-Lun, additional, Wu, Wen-Chih, additional, Lin, Chih-Lin, additional, Su, Wei-Wen, additional, Yang, Shengshun, additional, Wang, Chia-Chi, additional, Hu, Jui-Ting, additional, Mou, Lien-Juei, additional, Chen, Chun-Ting, additional, Huang, Yi-Hsiang, additional, Chang, Chun-Chao, additional, Huang, Jia-Sheng, additional, Chen, Guei-Ying, additional, Gao, Jian-Neng, additional, Tai, Chi-Ming, additional, Liu, Chun-Jen, additional, Lee, Mei-Hsuan, additional, Tsai, Pei-Chien, additional, Dai, Chia-Yen, additional, Kao, Jia-Horng, additional, Lin, Han-Chieh, additional, Chuang, Wan-Long, additional, Chen, Chiyi, additional, Tseng, Kuo-Chih, additional, and Yu, Ming-Lung, additional

Published
2022
Full Text
View/download PDF

90. Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos (t)ide analogue: 96-week results from a prospective multinational study

Author

Ogawa, Eiichi, primary, Jun, Dae Won, additional, Toyoda, Hidenori, additional, Hsu, Yao-Chun, additional, Yoon, Eileen, additional, Ahn, Sang Bong, additional, Do, Son, additional, Trinh, Huy, additional, Takahashi, Hirokazu, additional, Enomoto, Masaru, additional, Yasuda, Satoshi, additional, Tseng, Cheng-Hao, additional, Yeh, Ming-Lun, additional, Kawashima, Keigo, additional, Lee, Han Ah, additional, Inoue, Kaori, additional, Haga, Hiroaki, additional, Do, Ai-Thien, additional, Maeda, Mayumi, additional, Hoang, Joseph, additional, Cheung, Ramsey C., additional, Ueno, Yoshiyuki, additional, Eguchi, Yuichiro, additional, Furusyo, Norihiro, additional, Yu, Ming-Lung, additional, Tanaka, Yasuhito, additional, and Nguyen, Mindie, additional

Published
2022
Full Text
View/download PDF

98. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes

Author

Jang, Tyng‐Yuan, primary, Lin, Yi‐Hung, additional, Liang, Po‐Cheng, additional, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Liu, Ta‐Wei, additional, Wei, Yu‐Ju, additional, Hsu, Po‐Yao, additional, Yang, Jeng‐Fu, additional, Hou, Nai‐Jen, additional, Wang, Chih‐Wen, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Huang, Chung‐Feng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2022
Full Text
View/download PDF

99. Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients

Author

Batsaikhan, Batbold, primary, Huang, Ching-I., additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Lin, Yi-Hung, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Lin, Yi-Ching, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, Lee, Jin-Ching, additional, Yu, Ming-Lung, additional, Kuo, Hsing-Tao, additional, and Dai, Chia-Yen, additional

Published
2022
Full Text
View/download PDF

100. 328: REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VS NON-PI DIRECT ACTING ANTIVIRALS (DAAS) IN DECOMPENSATED HCV CIRRHOSIS: A REAL-C STUDY

Author

Wong, Yu Jun, primary, Tran, Sally, additional, Huang, Chung-Feng, additional, Hsu, Yao-Chun, additional, Preda, Carmen M., additional, Toyoda, Hidenori, additional, Liu, Joanne, additional, Jun, Dae Won, additional, Landis, Charles, additional, Huang, Daniel, additional, Gila, Andrei B., additional, Negoita, Livia, additional, Yasuda, Satoshi, additional, Tseng, Cheng-Hao, additional, Tsai, Pei-Chien, additional, Uojima, Haruki, additional, Nozaki, Akito, additional, Chuma, Makoto, additional, Atsukawa, Masanori, additional, itokawa, norio, additional, Iio, Etsuko, additional, Lam, Carla, additional, Watanabe, Tsunemasa, additional, Keisuke, Yokohama, additional, Abe, Hiroshi, additional, Enomoto, Masaru, additional, Tamori, Akihiro, additional, Lee, Dong-Hyun, additional, Jun, Mijung, additional, Maeda, Mayumi, additional, Nakanishi, Akiko, additional, Yeh, Ming-Lun, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Ishikawa, Toru, additional, Takaguchi, Koichi, additional, Senoo, Tomonori, additional, Trinh, Huy N., additional, Takahashi, Hirokazu, additional, Eguchi, Yuichiro, additional, Quek, Sabrina X., additional, Haga, Hiroaki, additional, Ogawa, Eiichi, additional, Wong, Grace L., additional, Buti, Maria, additional, Fukunishi, Shinya, additional, Ueno, Yoshiyuki, additional, Yuen, Man-Fung, additional, Tanaka, Yasuhito, additional, Lim, Seng Gee, additional, Cheung, Ramsey, additional, Yu, Ming-Lung, additional, and Nguyen, Mindie H., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results